Advertisement

Growth Factors in Human Germ Cell Cancer

  • W. H. MillerJr.
  • E. Dmitrovsky
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 123)

Abstract

A growing body of evidence suggests that malignancy often represents a failure of differentiation. Several model systems have been developed that show an inverse relationship between differentiation and malignancy. As tumor cells differentiate, they typically lose proliferative potential and the ability to cause tumors when implanted into susceptible hosts. Thus, an understanding of the cellular mechanisms of differentiation may yield insight into the mechanisms of the abnormal regulation of growth by cancer cells. Murine and human models of differentiation of tumor cells, including mouse erythroleukemia (MEL) cells, human leukemic cell lines, and mouse F9 teratocarcinoma cells, have been used to explore changes in the expression of important growth-regulated genes, such as cellular oncogenes and growth factors, as a function of differentiation induced in vitro. For example, a biphasic decline of c-myc and c-myb mRNA levels has been seen following dimethyl sulfoxide (DMSO) induction of MEL cells (Ramsey et al. 1986). Indeed, some authors have suggested a causal relationship between the downregulation of oncogene products and both differentiation and loss of malignancy. This has been supported by experiments showing that expression of transfected c-myc or c-myb genes into MEL cells blocks the induction of differentiation by DMSO (Dmitrovsky et al. 1986; Clarke et al. 1988). Differentiation of F9 cells can be induced by retinoic acid (RA) and dibutyryl cAMP and, as in MEL cells, is accompanied by specific changes in expression of protooncogenes, biochemical markers, developmentally active genes, and growth factors (reviewed in Miller et al. 1990a). These changes correlate with a decline in the malignant and proliferative potential of these differentiated cells (Strickland and Sawey 1980; Strickland and Mahdavi 1978).

Keywords

Retinoic Acid Retinoic Acid Treatment Teratocarcinoma Cell Germ Cell Cancer Human Germ Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrews PW (1988) Human teratocarcinomas. Biochim Biophys Acta 948: 17–36PubMedGoogle Scholar
  2. Clarke MF, Kukowska-Latallo JF, Westin E, Smith M, Prochownik E (1988) Constitutive expression of a c-myb cDNA blocks friend murine erythroleukemia cell differentiation. Mol Cell Biol 8: 884–892PubMedGoogle Scholar
  3. Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S (1986) Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukemia cell line. Nature 322: 748–750PubMedCrossRefGoogle Scholar
  4. Dmitrovsky E, Moy D, Miller WH Jr, Li A, Masui H (1990) Retinoic acid causes a decline in TGF-a expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line. Oncogene Res 5: 233–239PubMedGoogle Scholar
  5. Engström W, Rees AR, Heath JK (1985) Proliferation of a human embryonal carcinoma-derived cell line in serum-free medium: interrelationship between growth factor requirements and membrane receptor expression. J Cell Sci 73: 361–373PubMedGoogle Scholar
  6. Finkelstein R, Weinberg R (1988) Differential regulation of N-myc expression in F9 teratocarcinoma cells. Oncogene Res 3: 287–292Google Scholar
  7. Hauser CA, Joyner AL, Klein RD, Learned TK, Martin GR, Tjian R (1985) Expression of homologous homeo-box-containing genes in differentiated human teratocarcinoma cells and mouse embryos. Cell 43: 19–28PubMedCrossRefGoogle Scholar
  8. Hu L, Gudas LJ (1990) Cyclic AMP analogs and retinoic acid influence the expression of retinoic acid receptor a, ß, and gamma mRNAs in F9 teratocarcinoma cells. Mol Cell Biol 10: 391–396PubMedGoogle Scholar
  9. Krust A, Kastner P, Petkovich M, Zelent A, Chambon P (1989) A third human retinoic acid receptor, hRAR-gamma. Proc Natl Acad Sci USA 86: 5310–5314Google Scholar
  10. Melloni E, Pontremoli S, Michetti M, Sacco O, Cakiroglu AG, Jackson JF, Rifkind RA, Marks PA (1987) Protein kinase C activity and hexamethylene bisacetamide induced erythroleukemia cell differentiation. Proc Natl Acad Sci USA 84: 5282–5286PubMedCrossRefGoogle Scholar
  11. Miller WH Jr, Moy D, Li A, Grippo JF, Dmitrovsky E (1990a) Retinoic acid induces down-regulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line. Oncogene 5: 511–517PubMedGoogle Scholar
  12. Miller WH Jr, Kurie J, Moy D, Lucas DA, Grippo JF, Masui H, Dmitrovsky E (1990b) Growth factor downregulation is linked to differentiation and loss of tumorigenicity in human teratocarcinoma cells. To be publishedGoogle Scholar
  13. Ramsay RG, Ikeda K, Rifkind RA, Marks PA (1986) Changes in gene expression of erythroleukemia protooncogenes, globin genes, and cell division. Proc Natl Acad Sci USA 83: 6849–6853PubMedCrossRefGoogle Scholar
  14. Schofield PN, Engstrom W, Lee AJ, Biddle C, Graham CF (1987) Expression of cmyc during differentiation of the human teratocarcinoma line Tera-2. J Cell Sci 88: 57–64PubMedGoogle Scholar
  15. Strickland S, Mandavi V (1978) The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393–403PubMedCrossRefGoogle Scholar
  16. Strickland S, Sawey MJ (1980) Studies on the effect of retinoids on the differentiation of teratocarcinoma stem cells in vitro and in vivo. Dev Biol 78: 76–85PubMedCrossRefGoogle Scholar
  17. Wang S-Y, Gudas LJ (1983) Isolation of cDNA clones specific for collagen IV and laminin from mouse teratocarcinoma cells. Proc Natl Acad Sci USA 80: 5880–5884PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • W. H. MillerJr.
    • 1
  • E. Dmitrovsky
    • 1
  1. 1.Laboratory of Molecular Medicine, Department of MedicineMemorial Sloan-Kettering Cancer Center, Cornell University Medical CollegeNew YorkUSA

Personalised recommendations